glp-1 types Understanding receptor agonists and their impact on drug discovery GI Adverse Effects of Glucagon-Like

Whole-Body Cryotherapy in Athletes: From Therapy to Stimulation

Highlights GLP-1 medicines reduce fat and liver mass more rapidly than skeletal muscle (SKM) Running performance is maintained or improved in mice on GLP-1 medicine GLP-1 medicine modifies the SKM proteome despite similar weight loss as calorie restriction Patients on GLP-1 medicine slightly reduce SKM mass but largely maintain strength Summary The large decrease in body weight with glucagon-like peptide-1 (GLP-1) medicines raises concern about a loss of lean body mass (LBM) and skeletal muscle

Periodic breaks allow receptors to reset, ensuring that resumed use delivers full benefits

This makes it a cleaner and more selective choice compared to other peptides